GQG Partners’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $8.54M | Buy |
45,569
+45
| +0.1% | +$8.46K | 0.02% | 69 |
|
|
2026
Q1 | $8.87M | Sell |
45,524
-5,662
| -11% | -$1.09M | 0.01% | 57 |
|
|
2025
Q4 | $9.41M | Buy |
51,186
+7,204
| +16% | +$1.26M | 0.02% | 56 |
|
|
2025
Q3 | $6.75M | Sell |
43,982
-60,652
| -58% | -$9.18M | 0.01% | 63 |
|
|
2025
Q2 | $14.6M | Sell |
104,634
-623,881
| -86% | -$87.4M | 0.02% | 64 |
|
|
2025
Q1 | $107M | Sell |
728,515
-1,459,155
| -67% | -$211M | 0.17% | 50 |
|
|
2024
Q4 | $287M | Sell |
2,187,670
-549,901
| -20% | -$77M | 0.43% | 45 |
|
|
2024
Q3 | $427M | Buy |
2,737,571
+1,237,779
| +83% | +$200M | 0.67% | 39 |
|
|
2024
Q2 | $234M | Buy |
1,499,792
+1,390,045
| +1,267% | +$209M | 0.35% | 35 |
|
|
2024
Q1 | $14.9M | Sell |
109,747
-6,819,445
| -98% | -$903M | 0.02% | 46 |
|
|
2023
Q4 | $933M | Sell |
6,929,192
-93,744
| -1% | -$12.2M | 1.98% | 18 |
|
|
2023
Q3 | $951M | Sell |
7,022,936
-3,576,313
| -34% | -$488M | 2.2% | 17 |
|
|
2023
Q2 | $1.52B | Sell |
10,599,249
-173,445
| -2% | -$25.5M | 3.49% | 10 |
|
|
2023
Q1 | $1.5B | Buy |
10,772,694
+2,174,458
| +25% | +$293M | 3.91% | 8 |
|
|
2022
Q4 | $1.17B | Sell |
8,598,236
-590,630
| -6% | -$74.1M | 3.15% | 12 |
|
|
2022
Q3 | $1.01B | Sell |
9,188,866
-168,964
| -2% | -$21.4M | 2.91% | 16 |
|
|
2022
Q2 | $1.24B | Buy |
9,357,830
+217,489
| +2% | +$28.5M | 3.04% | 11 |
|
|
2022
Q1 | $1.21B | Sell |
9,140,341
-586,535
| -6% | -$70.3M | 2.81% | 12 |
|
|
2021
Q4 | $1.13B | Buy |
9,726,876
+486,699
| +5% | +$57.3M | 2.81% | 14 |
|
|
2021
Q3 | $1.11B | Buy |
9,240,177
+924,160
| +11% | +$108M | 3.04% | 13 |
|
|
2021
Q2 | $996M | Buy |
8,316,017
+610,290
| +8% | +$67M | 2.93% | 15 |
|
|
2021
Q1 | $766M | Buy |
7,705,727
+20,527
| +0.3% | +$2.06M | 2.8% | 15 |
|
|
2020
Q4 | $768M | Buy |
7,685,200
+2,308,235
| +43% | +$244M | 2.63% | 15 |
|
|
2020
Q3 | $589M | Buy |
5,376,965
+783,688
| +17% | +$87.2M | 2.02% | 18 |
|
|
2020
Q2 | $486M | Buy |
4,593,277
+624,581
| +16% | +$64.5M | 2.14% | 15 |
|
|
2020
Q1 | $355M | Buy |
3,968,696
+468,582
| +13% | +$44.1M | 2.44% | 13 |
|
|
2019
Q4 | $349M | Buy |
3,500,114
+535,502
| +18% | +$50.4M | 2.41% | 15 |
|
|
2019
Q3 | $264M | Buy |
2,964,612
+423,265
| +17% | +$36.7M | 2.69% | 15 |
|
|
2019
Q2 | $210M | Sell |
2,541,347
-36,288
| -1% | -$2.85M | 2.26% | 16 |
|
|
2019
Q1 | $208M | Buy |
2,577,635
+1,078,626
| +72% | +$85M | 2.58% | 17 |
|
|
2018
Q4 | $114M | Buy |
1,499,009
+154,615
| +12% | +$12.1M | 1.76% | 20 |
|
|
2018
Q3 | $106M | Buy |
+1,344,394
| New | +$102M | 1.73% | 21 |
|
Other funds holding AZN
EP
IA
GQG Partners's AZN Position: Q2 2026 in Review
GQG Partners increased its AstraZeneca (AZN) stake by 0.1% in Q2 2026, buying an estimated $8.46K and bringing the position to 45,569 shares worth $8.54M. The position accounts for 0.02% of the portfolio, ranked #69.
GQG Partners first reported a position in AZN in Q3 2018 and has held it in 32 quarters since. The position peaked at $1.52B in Q2 2023. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- GQG Partners held 45,569 shares of AstraZeneca worth $8.54M as of Q2 2026.
- GQG Partners bought 45 AstraZeneca shares in Q2 2026, an estimated $8.46K.
- AstraZeneca made up 0.02% of GQG Partners's portfolio in Q2 2026, its #69 holding.
- GQG Partners first reported a position in AstraZeneca in Q3 2018 and has held it in 32 quarters since.
- GQG Partners's AstraZeneca position peaked at $1.52B in Q2 2023.
- 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on GQG Partners's 13F filing for Q2 2026, filed 12 Aug 2026.